BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32546565)

  • 1. Population-based targeted sequencing of 54 candidate genes identifies
    Song H; Dicks EM; Tyrer J; Intermaggio M; Chenevix-Trench G; Bowtell DD; Traficante N; Group A; Brenton J; Goranova T; Hosking K; Piskorz A; van Oudenhove E; Doherty J; Harris HR; Rossing MA; Duerst M; Dork T; Bogdanova NV; Modugno F; Moysich K; Odunsi K; Ness R; Karlan BY; Lester J; Jensen A; Krüger Kjaer S; Høgdall E; Campbell IG; Lázaro C; Pujara MA; Cunningham J; Vierkant R; Winham SJ; Hildebrandt M; Huff C; Li D; Wu X; Yu Y; Permuth JB; Levine DA; Schildkraut JM; Riggan MJ; Berchuck A; Webb PM; Group OS; Cybulski C; Gronwald J; Jakubowska A; Lubinski J; Alsop J; Harrington P; Chan I; Menon U; Pearce CL; Wu AH; de Fazio A; Kennedy CJ; Goode E; Ramus S; Gayther S; Pharoah P
    J Med Genet; 2021 May; 58(5):305-313. PubMed ID: 32546565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
    Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine.
    Myszka A; Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
    Fam Cancer; 2018 Jul; 17(3):345-349. PubMed ID: 29052111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Risks Associated With Germline
    Yang X; Leslie G; Doroszuk A; Schneider S; Allen J; Decker B; Dunning AM; Redman J; Scarth J; Plaskocinska I; Luccarini C; Shah M; Pooley K; Dorling L; Lee A; Adank MA; Adlard J; Aittomäki K; Andrulis IL; Ang P; Barwell J; Bernstein JL; Bobolis K; Borg Å; Blomqvist C; Claes KBM; Concannon P; Cuggia A; Culver JO; Damiola F; de Pauw A; Diez O; Dolinsky JS; Domchek SM; Engel C; Evans DG; Fostira F; Garber J; Golmard L; Goode EL; Gruber SB; Hahnen E; Hake C; Heikkinen T; Hurley JE; Janavicius R; Kleibl Z; Kleiblova P; Konstantopoulou I; Kvist A; Laduca H; Lee ASG; Lesueur F; Maher ER; Mannermaa A; Manoukian S; McFarland R; McKinnon W; Meindl A; Metcalfe K; Mohd Taib NA; Moilanen J; Nathanson KL; Neuhausen S; Ng PS; Nguyen-Dumont T; Nielsen SM; Obermair F; Offit K; Olopade OI; Ottini L; Penkert J; Pylkäs K; Radice P; Ramus SJ; Rudaitis V; Side L; Silva-Smith R; Silvestri V; Skytte AB; Slavin T; Soukupova J; Tondini C; Trainer AH; Unzeitig G; Usha L; van Overeem Hansen T; Whitworth J; Wood M; Yip CH; Yoon SY; Yussuf A; Zogopoulos G; Goldgar D; Hopper JL; Chenevix-Trench G; Pharoah P; George SHL; Balmaña J; Houdayer C; James P; El-Haffaf Z; Ehrencrona H; Janatova M; Peterlongo P; Nevanlinna H; Schmutzler R; Teo SH; Robson M; Pal T; Couch F; Weitzel JN; Elliott A; Southey M; Winqvist R; Easton DF; Foulkes WD; Antoniou AC; Tischkowitz M
    J Clin Oncol; 2020 Mar; 38(7):674-685. PubMed ID: 31841383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare, protein-truncating variants in
    Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
    J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.
    Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D
    Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
    Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
    PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
    Southey MC; Goldgar DE; Winqvist R; Pylkäs K; Couch F; Tischkowitz M; Foulkes WD; Dennis J; Michailidou K; van Rensburg EJ; Heikkinen T; Nevanlinna H; Hopper JL; Dörk T; Claes KB; Reis-Filho J; Teo ZL; Radice P; Catucci I; Peterlongo P; Tsimiklis H; Odefrey FA; Dowty JG; Schmidt MK; Broeks A; Hogervorst FB; Verhoef S; Carpenter J; Clarke C; Scott RJ; Fasching PA; Haeberle L; Ekici AB; Beckmann MW; Peto J; Dos-Santos-Silva I; Fletcher O; Johnson N; Bolla MK; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Marme F; Burwinkel B; Yang R; Guénel P; Truong T; Menegaux F; Sanchez M; Bojesen S; Nielsen SF; Flyger H; Benitez J; Zamora MP; Perez JI; Menéndez P; Anton-Culver H; Neuhausen S; Ziogas A; Clarke CA; Brenner H; Arndt V; Stegmaier C; Brauch H; Brüning T; Ko YD; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Antonenkova NN; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Spurdle AB; Investigators K; ; Wauters E; Smeets D; Beuselinck B; Floris G; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Olson JE; Vachon C; Pankratz VS; McLean C; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Kristensen V; Alnæs GG; Zheng W; Hunter DJ; Lindstrom S; Hankinson SE; Kraft P; Andrulis I; Knight JA; Glendon G; Mulligan AM; Jukkola-Vuorinen A; Grip M; Kauppila S; Devilee P; Tollenaar RA; Seynaeve C; Hollestelle A; Garcia-Closas M; Figueroa J; Chanock SJ; Lissowska J; Czene K; Darabi H; Eriksson M; Eccles DM; Rafiq S; Tapper WJ; Gerty SM; Hooning MJ; Martens JW; Collée JM; Tilanus-Linthorst M; Hall P; Li J; Brand JS; Humphreys K; Cox A; Reed MW; Luccarini C; Baynes C; Dunning AM; Hamann U; Torres D; Ulmer HU; Rüdiger T; Jakubowska A; Lubinski J; Jaworska K; Durda K; Slager S; Toland AE; Ambrosone CB; Yannoukakos D; Swerdlow A; Ashworth A; Orr N; Jones M; González-Neira A; Pita G; Alonso MR; Álvarez N; Herrero D; Tessier DC; Vincent D; Bacot F; Simard J; Dumont M; Soucy P; Eeles R; Muir K; Wiklund F; Gronberg H; Schleutker J; Nordestgaard BG; Weischer M; Travis RC; Neal D; Donovan JL; Hamdy FC; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Schaid DJ; Kelley JL; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Butterbach K; Park J; Kaneva R; Batra J; Teixeira MR; Kote-Jarai Z; Olama AA; Benlloch S; Renner SP; Hartmann A; Hein A; Ruebner M; Lambrechts D; Van Nieuwenhuysen E; Vergote I; Lambretchs S; Doherty JA; Rossing MA; Nickels S; Eilber U; Wang-Gohrke S; Odunsi K; Sucheston-Campbell LE; Friel G; Lurie G; Killeen JL; Wilkens LR; Goodman MT; Runnebaum I; Hillemanns PA; Pelttari LM; Butzow R; Modugno F; Edwards RP; Ness RB; Moysich KB; du Bois A; Heitz F; Harter P; Kommoss S; Karlan BY; Walsh C; Lester J; Jensen A; Kjaer SK; Høgdall E; Peissel B; Bonanni B; Bernard L; Goode EL; Fridley BL; Vierkant RA; Cunningham JM; Larson MC; Fogarty ZC; Kalli KR; Liang D; Lu KH; Hildebrandt MA; Wu X; Levine DA; Dao F; Bisogna M; Berchuck A; Iversen ES; Marks JR; Akushevich L; Cramer DW; Schildkraut J; Terry KL; Poole EM; Stampfer M; Tworoger SS; Bandera EV; Orlow I; Olson SH; Bjorge L; Salvesen HB; van Altena AM; Aben KK; Kiemeney LA; Massuger LF; Pejovic T; Bean Y; Brooks-Wilson A; Kelemen LE; Cook LS; Le ND; Górski B; Gronwald J; Menkiszak J; Høgdall CK; Lundvall L; Nedergaard L; Engelholm SA; Dicks E; Tyrer J; Campbell I; McNeish I; Paul J; Siddiqui N; Glasspool R; Whittemore AS; Rothstein JH; McGuire V; Sieh W; Cai H; Shu XO; Teten RT; Sutphen R; McLaughlin JR; Narod SA; Phelan CM; Monteiro AN; Fenstermacher D; Lin HY; Permuth JB; Sellers TA; Chen YA; Tsai YY; Chen Z; Gentry-Maharaj A; Gayther SA; Ramus SJ; Menon U; Wu AH; Pearce CL; Van Den Berg D; Pike MC; Dansonka-Mieszkowska A; Plisiecka-Halasa J; Moes-Sosnowska J; Kupryjanczyk J; Pharoah PD; Song H; Winship I; Chenevix-Trench G; Giles GG; Tavtigian SV; Easton DF; Milne RL
    J Med Genet; 2016 Dec; 53(12):800-811. PubMed ID: 27595995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of germline PALB2 mutations among women with epithelial ovarian cancer.
    Kotsopoulos J; Sopik V; Rosen B; Fan I; McLaughlin JR; Risch H; Sun P; Narod SA; Akbari MR
    Fam Cancer; 2017 Jan; 16(1):29-34. PubMed ID: 27631815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.
    Gonzalez A; Del Greco F; Vargas-Roig L; Brun B; Tabares G; Mampel A; Montes C; Martin C; Lopez M; Rossi N; Bruno L; Ponce C; Quaglio P; Yanzi A; Acevedo S; Lugo L; Lopez Breccia P; Avila S; Sisterna S; Del Castillo MS; Vazquez M; Nuñez LM
    Breast Cancer Res Treat; 2022 Jul; 194(2):403-412. PubMed ID: 35610400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
    Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
    J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
    Tischkowitz M; Sabbaghian N; Hamel N; Pouchet C; Foulkes WD; Mes-Masson AM; Provencher DM; Tonin PN
    BMC Med Genet; 2013 Jan; 14():5. PubMed ID: 23302520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
    Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
    Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
    Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exome sequencing identifies
    Dicks EM; Tyrer JP; Ezquina S; Jones M; Baierl J; Peng PC; Diaz M; Goode E; Winham SJ; Dörk T; Van Gorp T; De Fazio A; Bowtell D; Odunsi K; Moysich K; Pavanello M; Campbell I; Brenton JD; Ramus SJ; Gayther SA; Pharoah PDP
    medRxiv; 2024 Apr; ():. PubMed ID: 38633804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants.
    Jervis S; Song H; Lee A; Dicks E; Tyrer J; Harrington P; Easton DF; Jacobs IJ; Pharoah PP; Antoniou AC
    J Med Genet; 2014 Feb; 51(2):108-13. PubMed ID: 24277755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.